In a breakthrough for clinical nutrition and pediatric neurology, Jolly Healthcare announced the national launch of KETOJOL 4:1. Standardized to a precise 4:1 fat-to- (protein + carbohydrate) ratio, KETOJOL marks a monumental category milestone as India’s first ketogenic diet formulation. Setting a new benchmark for clinical integrity, the product is manufactured under a specialized pharmaceutical license, guaranteeing gold-standard quality, safety, and precise formulation distinct from standard food-grade manufacturing.
Drug-Resistant Epilepsy (DRE) affects nearly one in three epilepsy patients, who continue to suffer from uncontrolled seizures despite multi-drug Anti-Epileptic Drug (AED) therapy. Published clinical literature establishes that classical Ketogenic Dietary Therapy (KDT)—delivering 90 per cent of total calories from fat—can achieve a ≥50 per cent reduction in seizure frequency in 50–60 per cent of refractory pediatric cases by utilizing ketones as an alternative energy source to stabilize neuronal hyperexcitability.
Addressing the landmark launch, Avish Jolly, MD & CEO of Jolly Healthcare, stated: "For decades, families managing Drug-Resistant Epilepsy have faced severe execution barriers—from complex home calculations and poor pediatric palatability to long-term nutritional deficits and gastrointestinal distress. By securing classification under a pharmaceutical manufacturing license, KETOJOL 4:1 bridges the gap between strict clinical efficacy and real-world compliance. Enhanced with prebiotics (Inulin) for superior GI tolerance and formulated for child acceptance, our goal is to empower pediatric neurologists and dietitians with a practical, high-precision solution that supports uninterrupted childhood."
Engineered as a comprehensive medical nutrition solution, KETOJOL 4:1 addresses the key clinical limitations of traditional ketogenic diets. The inclusion of prebiotics (Inulin) improves gastrointestinal tolerance, while its enriched micronutrient profile helps mitigate long-term nutritional deficiencies commonly associated with strict ketogenic regimens.
Jolly Healthcare is executing an institution-first rollout across tertiary care hospitals, paediatric neurology centres, and specialized dietetic clinics. The launch is supported by the 'KETOJOL Keto Support Program', providing precision digital weighing protocols (0.1g accuracy) and caregiver education to ensure exact dosage administration. Strictly classified as an, KETOJOL™ 4:1 is intended for use under qualified medical supervision as an adjunct dietary therapy alongside prescribed clinical management.
